Human monoclonal antibodies: The residual challenge of antibody immunogenicity

Methods in Molecular Biology

Volumn 1060, Issue , 2014, Pages 1-8

  Waldmann, Herman ^a,b  

^a UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Adjuvanticity; High dose tolerance; Humanized and human antibodies; Immunogenicity; Therapeutic antibodies

Indexed keywords

HUMAN MONOCLONAL ANTIBODY; IMMUNOGLOBULIN; POLYCLONAL ANTIBODY; ANTIBODY;

ANTIGEN ANTIBODY COMPLEX; ANTIGEN BINDING; ARTICLE; B LYMPHOCYTE; HELPER CELL; HUMAN; IMMUNOGENICITY; IMMUNOGLOBULIN AGGREGATE; IMMUNOLOGICAL TOLERANCE; NONHUMAN; PRIORITY JOURNAL; RISK;

RODENTIA;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; HUMANS; IMMUNE TOLERANCE;

EID: 84931271297     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-62703-586-6_1     Document Type: Article

References (21)

1. Kohler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495-4
2. Steinitz M et al (1977) EB virus-induced B lymphocyte cell lines producing specific antibody. Nature 269:420-4
3. Bruggemann M et al (1989) The immunogenicity of chimeric antibodies. J Exp Med 170: 2153-2
4. Jones PT et al (1986) Replacing the complementarity- determining regions in a human antibody with those from a mouse. Nature 321:522-5
5. Riechmann L et al (1988) Reshaping human antibodies for therapy. Nature 332: 323-3
6. Bruggemann M et al (1989) A repertoire of monoclonal antibodies with human heavy chains from transgenic mice. Proc Natl Acad Sci USA 86:6709-6
7. Lonberg N (2005) Human antibodies from transgenic animals. Nat Biotechnol 23: 1117-1
8. Winter G et al (1994) Making antibodies by phage display technology. Annu Rev Immunol 12:433-4
9. Clark M (2000) Antibody humanization: a case of the "Emperor's new clothes"? Immunol Today 21:397-402
10. Chiller JM et al (1970) Cellular sites of immunologic unresponsiveness. Proc Natl Acad Sci USA 65:551-556
11. Benjamin RJ et al (1986) Tolerance to rat monoclonal antibodies. Implications for serotherapy. J Exp Med 163:1539-1552
12. Waldmann H et al (2008) Reprogramming the immune system: co-receptor blockade as a paradigm for harnessing tolerance mechanisms. Immunol Rev 223:361-370
13. Rebello PR et al (1999) Anti-globulin responses to rat and humanized CAMPATH-1 monoclonal antibody used to treat transplant rejection. Transplantation 68:1417-1420
14. Eichmann K (1973) Idiotype expression and the inheritance of mouse antibody clones. J Exp Med 137:603-621
15. Somerfield J et al (2010) A novel strategy to reduce the immunogenicity of biological therapies. J Immunol 185:763-768
16. Feldmann M, Maini RN (2001) Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 19:163-196
17. De Groot AS, Scott DW (2007) Immunogenicity of protein therapeutics. Trends Immunol 28:482-490
18. Harding FA et al (2010) The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. MAbs 2:256-265
19. Isaacs JD, Waldmann H (1994) Helplessness as a strategy for avoiding antiglobulin responses to therapeutic monoclonal antibodies. Ther Immunol 1:303-312
20. Gilliland LK et al (1999) Elimination of the immunogenicity of therapeutic antibodies. J Immunol 162:3663-3671
21. Waldmann HF,Gillilkand MK, Graca L (2008) Therapeutic antibodies. US 7,465,790 B2